SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Nordenskjöld M) srt2:(2000-2004)"

Search: WFRF:(Nordenskjöld M) > (2000-2004)

  • Result 1-7 of 7
Sort/group result
   
EnumerationReferenceCoverFind
1.
  •  
2.
  • Ek, Sara, et al. (author)
  • Gene expression profiling of mantle cell lymphonas
  • 2003
  • In: Immunology Letters (Abstracts of the 15th European Immunology Congress (EFIS 2003)). - 0165-2478 .- 1879-0542. ; 87:1-3, s. 01-24
  • Conference paper (other academic/artistic)
  •  
3.
  •  
4.
  •  
5.
  • Stål, Olle, 1952-, et al. (author)
  • ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer
  • 2000
  • In: Annals of Oncology. - 0923-7534 .- 1569-8041. ; 11:12, s. 1545-1550
  • Journal article (peer-reviewed)abstract
    • Aim:We aimed to study the importance of erbB2 status in early stage postmenopausal breast cancer for patients who participated in a trial of five vs. two years of adjuvant tamoxifen.Patients and methods: We analysed the erbB2 status of the tumours from 577 patients participating in the trial, either by a DNA amplification assay (n=181) or by measurement of the protein level with flow cytometry (n=396).Results: ErbB2 was overexpressed or gene amplified in 102 of the patients (18%). Overall, erbB2-positive patients had a significantly lower recurrence-free probability than others, 62% at five years as compared to 83%, and showed a significantly decreased breast cancer survival rate (P=0.0007). ErbB2 status was significantly associated with recurrence and death in Cox multivariate analysis, adjusting for nodal status, tumour size and estrogen receptor status. The relative risk of recurrence (RR) for five vs. two years of tamoxifen was analysed in relation to erbB2 status for patients still disease-free two years after surgery. Whereas erbB2-negative patients showed significant benefit from prolonged treatment (RR=0.62, 95% confidence interval (95% CI): 0.42–0.93), no benefit was evident for erbB2-positive patients (RR=1.1, 95% CI: 0.41–3.2). When the same analysis was restricted to ER-positive patients a similar difference in relative hazard was obtained but the difference was not strictly significant (P=0.065).Conclusions: For early stage breast cancer patients treated with adjuvant tamoxifen, overexpression of erbB2 is an independent marker of poor prognosis. The results suggest that overexpression decreases the benefit from prolonged tamoxifen treatment.
  •  
6.
  •  
7.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-7 of 7

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view